Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | QPCT | Q16769 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128170 | 0.83 | KMT2A (0.44) | SMN1; SMN2POLBLMNAKDM4EALDH1A1 | |
| SCHEMBL5127666 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2POLBLMNAKDM4EALDH1A1 | |
| SCHEMBL5124130 | 0.83 | L3MBTL1 (0.46) | LMNAKMT2A | |
| SCHEMBL5256428 | 0.81 | CYP2C19 (0.46) | SMN1; SMN2LMNAMAPK1KDM4EALDH1A1 | |
| SCHEMBL5122423 | 0.81 | CCR2 (0.45) | SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL5123558 | 0.80 | CCR2 (0.46) | SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL5249177 | 0.80 | GAA (0.47) | SMN1; SMN2LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL5116178 | 0.80 | GAA (0.47) | SMN1; SMN2LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL5128046 | 0.79 | ALDH1A1 (0.48) | SMN1; SMN2POLBLMNAKDM4EALDH1A1 | |
| SCHEMBL5118583 | 0.79 | KMT2A (0.44) | SMN1; SMN2MAPK1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| EP-1441734-B1 | DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-02-28 | — | — | EP | disclosed |
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | SMN1; SMN2 4143/4885POLB 101/4885LMNA 4057/4885 |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | SMN1; SMN2 4190/4885POLB 112/4885LMNA 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.